Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

GMC remote prescribing principles guidance

Covering key principles for remote prescribing and an algorithm for deciding when to perform remote consultations
Published: 17 Sep 2021

NICE CKD guideline

Covering the assessment and management of chronic kidney disease, including pharmacotherapy
Published: 14 Sep 2021

ABCD position on cardiovascular impact of glucose-lowering drugs

Key recommendations from the ABCD position statement on new glucose-lowering drugs concerning their cardiovascular impact on people with diabetes
Published: 09 Sep 2021

NICE COVID-19 management

Summary of NICE guidance on the management of COVID-19 in children, young people, and adults in primary care settings
Published: 08 Sep 2021

NICE CKD and anaemia guideline

Covering the assessment and management of anaemia in people with chronic kidney disease
Published: 06 Sep 2021

Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes

This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.
Published: 06 Sep 2021

Visit the Guidelines website

NICE recommends Ultomiris for NHS use in patients with rare blood disorders

NICE recommends Ultomiris for NHS use in patients with rare blood disorders 21 May 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Alexion’s long-acting C5 complement inhibitor Ultomiris for NHS use in patients with rare blood disorders. ... NICE has approved Ultomiris for the treatment of aHUS and

NICE recommends Keytruda for colorectal cancer patients with rare mutations

NICE recommends Keytruda for colorectal cancer patients with rare mutations 14 May 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Keytruda for NHS use as a first-line treatment for colorectal cancer patients with rare mutations. ... As a result, NICE recommends that Keytruda treatment should be

NICE sets out plans for ‘ambitious’ five-year strategy

NICE sets out plans for ‘ambitious’ five-year strategy 20 Apr 2021
NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments. ... learning will bring digital health in disease prevention and self care to the fore,” said Sharmila Nebhrajani, NICE chair.

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

Alexion and NICE agree confidential discount for Ultomiris use on the NHS 16 Apr 2021
NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.

NICE rejects Keytruda for advanced bladder cancer in final guidance

NICE rejects Keytruda for advanced bladder cancer in final guidance 18 Mar 2021
Following this rejection, MSD appealed the decision, although NICE has upheld its previous guidance not to recommend Keytruda as a second-line treatment for advanced bladder cancer patients. ... In a statement issued today, NICE said that although

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...